SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Actual costs of cancer drugs in 15 European countries
4 references·4 citing·27 second hop
Actual costs of cancer drugs in 15 European countries (2015)Actual costs of cancer drugs in 15 Europe…American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)American Society of Clinical …A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)A standardised, generic, vali…Economic burden of cancer across the European Union: a population-based cost analysis (2013)Economic burden of cancer acr…Delivering affordable cancer care in high-income countries (2011)Delivering affordable cancer …Integrative Review of Managed Entry Agreements: Chances and Limitations (2020)Integrative Review of Managed…Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing (2019)Evolution of Average European…Can Price Transparency Contribute to More Affordable Patient Access to Medicines? (2017)Can Price Transparency Contri…Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries (2016)Relative effectiveness assess…Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Economic Burden of Bladder Cancer Across the European Union (2015)Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050 (2023)The price of innovation: new estimates of drug development costs (2003)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Delivery of affordable and equitable cancer care in India (2014)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)GRADE guidelines: 3. Rating the quality of evidence (2011)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Net Health Benefits (1998)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Essential medicines for universal health coverage (2016)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions (2012)Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs (2018)Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies (2021)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Pharmaceutical Price Controls and Entry Strategies (2007)How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis (2016)Cochrane Handbook for Systematic Reviews of Interventions (2008)Pricing in the Market for Anticancer Drugs (2015)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Evidence-based public policy making for medicines across countries: findings and implications for the future (2021)
this work references cited by second hop

References

  • 2013Economic burden of cancer across the European Union: a population-based cost analysis1,009 cited
  • 2015American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options916 cited
  • 2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)817 cited
  • 2011Delivering affordable cancer care in high-income countries720 cited

Cited by

  • 2016Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries59 cited
  • 2020Integrative Review of Managed Entry Agreements: Chances and Limitations56 cited
  • 2017Can Price Transparency Contribute to More Affordable Patient Access to Medicines?55 cited
  • 2019Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing53 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work